Clinical trials: CIS
Multiple Sclerosis
An Observational Study on the Progression of Clinically Isolated Syndrome to Multiple Sclerosis Over a 2-year Period
This is a prospective, multicentric, observational study with a 2 years recruitment period. The purpose of the study is to observe the multiple sclerosis (MS) progression of subjects since their first episode of neurological…
- Trial name
- NEO (NCT01112657)
- Where
- 6 sites in Taiwan
- Volunteers
- 154 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Clinically Isolated Syndrome
A Prospective Study Looking at the Use of Rebif® in Subjects With Clinically Isolated Syndrome
The primary objective of this initiative is to assess the effectiveness of subcutaneous (sc) interferon (IFN) beta - 1a, (Rebif®), versus No Treatment in delaying the conversion to Clinically Definite Multiple Sclerosis (CDMS) …
- Trial name
- CIS-ON (NCT00287079)
- Testing
- Rebif®, No Treatment
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
This study aims to evaluate potential predictors of adherence by investigating a representative cohort of MS patients in Germany treated with Betaferon
- Trial name
- BETAPREDICT (NCT02486640)
- Testing
- Interferon beta-1b (Betaferon, BAY86-5046), Betaconnect Autoinjector
- Where
- Germany
- Volunteers
- 162 people
- Sponsor
- Bayer
Lung Transplant
Cyclosporine Inhalation Solution (CIS) in Lung Transplant Recipients
Currently there are no approved therapies for lung transplant recipients in the United States (US). Treatment with CIS following lung transplantation has previously been demonstrated to result in a clinically meaningful…
- Trial name
- NCT00633373
- Testing
- Cyclosporine Inhalation Solution
- Where
- 8 sites in United States
- Sponsor
- APT Pharmaceuticals, Inc.
Multiple Sclerosis
Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study
The planned study will be a prospective, non-interventional, observational cohort study using the structure of a registry. Medication usage behavior will be observed for 6 months, while documentation behavior on the wellness…
- Trial name
- PROmyBETAapp (NCT03134573)
- Testing
- Interferon beta-1b (Betaferon, BAY86-5046), Betaconnect auto-injector, myBETAapp
- Where
- Germany
- Volunteers
- 96 people
- Sponsor
- Bayer
Atopic Dermatitis
Investigation of the Efficacy of 2.5% and 5% Cis-urocanic Acid in Patients With Moderate or Severe Atopic Dermatitis
The purpose of this study is to evaluate dose response, safety, tolerability and efficacy of 2.5% and 5% cis-UCA in comparison to placebo and active comparator in the treatment of adult patients with moderate or severe chronic…
- Trial name
- NCT01320579
- Testing
- Cis-UCA 2.5% emulsion cream, Cis-UCA 5% emulsion cream, Protopic® 0.1% ointment
- Where
- 7 sites in Finland
- Volunteers
- 159 people
- Sponsor
- BioCis Pharma Ltd
Knee Osteoarthritis
A Study to Compare Levels of Capsaicin After Intra-Articular Injection and Topical Application in Patients With Painful Knee Osteoarthritis
This is a Phase 1b, open-label, two-period, randomized crossover study in adult male and female participants with painful knee osteoarthritis.
- Trial name
- NCT03576508
- Testing
- CNTX-4975-05, Qutenza, Lidocaine (without epinephrine)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Centrexion Therapeutics
Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
Researchers are looking for new ways to treat people with high-risk non-muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder but has not spread to the bladder muscle or…
- Conditions
- Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ
- Trial name
- NCT06833073
- Testing
- Intismeran autogene, BCG
- Where
- 89 sites in United States, Argentina and 17 more
- Volunteers
- 308 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-muscle Invasive Bladder Cancer
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
TARA-002-101-Ph2 is an open-label study to investigate the safety and efficacy of intravesical instillation of TARA-002 in adults 18 years of age or older with high-grade CIS NMIBC (± Ta/T1).
- Trial name
- ADVANCED-2 (NCT05951179)
- Testing
- TARA-002
- Where
- 78 sites in United States, Argentina and 5 more
- Volunteers
- 131 people
- Sponsor
- Protara Therapeutics
Urinary Bladder Neoplasms
A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102
This is an open label, multicenter, phase 1/1b study to assess safety/tolerability and preliminary clinical activity of E7766 as a single agent administered intravesically in participants with NMIBC.
- Trial name
- NCT04109092
- Testing
- E7766
- Where
- 9 sites in United States
- Sponsor
- Eisai Inc.
Bowen's Disease, Cutaneous Squamous Cell Carcinoma in Situ
Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With isSCC
This is an open label, dose escalation study to evaluate the safety and efficacy of intralesional injection of STP705 in adult patients with Cutaneous Squamous Cell Carcinoma in situ (isSCC, Bowen's disease).
- Trial name
- NCT04293679
- Testing
- STP705
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sirnaomics
Multiple Sclerosis
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
The primary objective was to demonstrate the effect of teriflunomide (HMR1726) (14 milligram per day [mg/day] and 7 mg/day), in comparison to placebo, for reducing conversion of participants presenting with their first clinical…
- Trial name
- TOPIC (NCT00622700)
- Testing
- Teriflunomide
- Where
- 131 sites in United States, Australia and 19 more
- Volunteers
- 618 people
- Sponsor
- Sanofi
Nasopharyngeal Carcinoma
A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC Subjects
This is an open-label, single center, non-randomized, phase I trial to evaluate safety and efficacy of using the combination treatment of SHR-1210, gemcitabine and cis-platinum by recurrent and metastatic NPC.
- Trial name
- NCT03121716
- Testing
- SHR-1210, Gemcitabine, cis-platinum
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Non-muscle Invasive Bladder Cancer
Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a)
This study is an open-label dose escalation study (Phase 1a) to investigate the safety and toxicity of intravesical treatment of high-grade NMIBC (HGTa or CIS, including CIS with concomitant Ta) after transurethral resection of…
- Trial name
- ADVANCED-1 (NCT05085977)
- Testing
- TARA-002
- Where
- 14 sites in United States, Moldova and 2 more
- Volunteers
- 12 people
- Sponsor
- Protara Therapeutics
Metastatic Breast Cancer, Stage IV Breast Cancer
BP-C1 in Metastatic Breast Cancer Patients
This study is an open label, non-randomized phase I single-armed study in women with metastatic breast cancer (MBC) who have previously undergone all available standard chemotherapy regimens.
- Trial name
- NCT01861509
- Testing
- BP-C1
- Where
- 2 sites in Israel, Thailand
- Volunteers
- 10 people
- Sponsor
- Meabco A/S
Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
This study aims to evaluate the efficacy and safety of Cretostimogene in patients with BCG-unresponsive high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without Ta/T1 papillary tumors.
- Trial name
- NCT07283835
- Testing
- Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside
- Where
- 14 sites in China
- Volunteers
- 16 people
- Sponsor
- Lepu Biopharma Co., Ltd.
Cervix Cancer, Endometrium Cancer
Probe-based and Needle-based Confocal Laser Endomicroscopy During Gynaecological Procedures.
The protocol aims at demonstrating the technical feasibility and safety of doing endomicroscopic imaging (both probe-based confocal laser endomicroscopy (pCLE) and needle-based confocal laser endomicroscopy, nCLE) during…
- Conditions
- Cervix Cancer, Endometrium Cancer, Ovarian Cancer, Carcinoma in Situ of Fallopian Tube
- Trial name
- NCT02221076
- Testing
- Confocal Laser Endomicroscopy (CLE)
- Where
- France
- Volunteers
- 16 people
- Sponsor
- Mauna Kea Technologies
Carcinoma, Non-small Cell Lung Cancer
Phase I Imaging Study Evaluating Gem/Cis or Gem/Carbo for Participants With Non-Small Cell Lung Cancer (MK-0000-083 AM3)
This study will use imaging to look at tumor response to combination chemotherapy of gemcitabine (Gem) and cisplatin (Cis) or gemcitabine and carboplatin (Carbo) in non small cell lung cancer (NSCLC).
- Trial name
- NCT00599755
- Testing
- Comparator: CT or MRI and FDG-PET, Gemcitabine and Cisplatin or Gemcitabine and Carboplatin
- Volunteers
- 68 people
- Sponsor
- Merck Sharp & Dohme LLC
Acute Exacerbation of Remitting Relapsing Multiple Sclerosis, Clinically Isolated Syndrome
Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS)
Patients with an acute exacerbation of Relapsing-Remitting Multiple Sclerosis or with Clinically Isolated Syndrome receive either one single infusion of Nanocort or three daily infusions of SoluMedrol.
- Trial name
- NCT01039103
- Testing
- PEG-liposomal prednisolone sodium phosphate, Methylprednisolone
- Where
- 8 sites in Belgium, Germany and 1 more
- Volunteers
- 15 people
- Sponsor
- Lakefront Biotherapeutics NV
Oral Mucositis, Carcinoma in Situ of Upper Respiratory Tract
Efficacy of MUCIPLIQ on the Incidence of Radio-chemotherapy-induced Mucositis in Patients Suffering From Oral Cancer
MUCIPLIQ is a nanopolymer engineered to mimic glycosaminoglycans such as heparan sulfates. Glycosaminoglycans are involved 1) in the stabilization of cells micro-environment, known as extracellular matrix, by binding to…
- Trial name
- MUCIPLIQ (NCT01840436)
- Testing
- MUCIPLIQ
- Where
- 5 sites in France
- Volunteers
- 136 people
- Sponsor
- Organ, Tissue, Regeneration, Repair and Replacement